SEATTLE, July 17, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $12.50 per share pursuant to its existing shelf registration statement. NanoString has granted to the underwriters of the offering a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price. NanoString intends to use the net proceeds of the offering for the development and launch of the Company’s Digital Spatial Profiling platform, the continued commercialization of the Company’s portfolio of nCounter-based products, and for general corporate purposes and working capital. The offering is expected to close on or about July 20, 2018, subject to customary closing conditions.
J.P. Morgan and UBS Investment Bank are acting as joint book-running managers for the offering. Baird is acting as lead manager for the offering.
A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on August 30, 2017, amended on September 11, 2017 and declared effective by the SEC on September 14, 2017. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus, may also be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, 25th floor, New York, NY 10019, or by phone at 888-827-7275 or by email at [email protected]
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Vice President, Investor Relations & Corporate Communications
Latest posts by Nasdaq NewsFeed (see all)
- Ultrasound Probe Disinfection Market by Product (Instrument, Service, Consumables), Probe Type (Linear & Endocavity Transducer), End User (Hospitals) – Global Forecast to 2023 - October 15, 2018
- Contrast Agents/Media Market, 2025 - October 15, 2018
- $4.37 Bn Airport Information Systems Market by End Use, Type, Airport, Application & Region – Global Forecast to 2023 - October 15, 2018